Press release
Rising Multiple Myeloma Cases Fuel Growth In The Abecma Market: Key Factor Driving The Growth In The Abecma Market
Abecma Market
What Is the Projected Growth of the Abecma Market?
In the last few years, the abecma market size has seen a high compound annual growth rate (HCAGR) of XX%. The projections suggest a growth from $XX million in 2024 to $XX million in 2025, translating to a compound annual growth rate (CAGR) of XX%. This growth during the historic period owes itself to factors like the approval of abecma for relapsed/refractory multiple myeloma, developments in car t-cell therapy, rising cases of multiple myeloma, its high effectiveness in treatment-resistant cases, and an increase in research and development investments.
The market size of abcema is projected to experience an XX (FCAGR) increase in the upcoming years, predicted to reach $XX million in 2029 with a compound annual growth rate (CAGR) of XX%. The projected growth during the forecast period is due to factors including the increasing incidence of multiple myeloma, broadening approved indications, advancements in personalized healthcare, worldwide market development, enhanced production and cost lowering. Key trends during the forecast period comprises of accelerated adoption in preceding treatment lines, geographical market growth, tech improvements in car t-cell therapy, strategies for combination therapy, precision and personalized medicine, and a heightened emphasis on relapsed/refractory multiple myeloma.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19847
What Are the Different Abecma Market Segments?
The abecma market covered in this report is segmented -
1) By Indication: Multiple Myeloma; B-Cell Lymphoma (BCL); Acute Lymphoblastic Leukemia (ALL)
2) By End User: Adult; Geriatric
3) By Distribution Channel: Hospitals And clinics; Retail And Speciality Pharmacies; Online Pharmacies
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19847&type=smp
What Are the Primary Drivers Shaping the Abecma Market?
The escalating incidence of multiple myeloma is anticipated to boost the growth of the abecma market. Multiple myeloma, a form of blood cancer that impacts plasma cells, a kind of white blood cell in bone marrow, has seen increasing prevalence due to an aging population, advancements in diagnostic methods, and heightened disease awareness. Abecma, a CAR T-cell therapy, serves as a treatment for multiple myeloma by using genetically altered immune cells to detect and eradicate cancerous plasma cells. This presents a unique treatment method for individuals with relapsed or refractory disease variations. For example, in January 2024, the American Cancer Society, a non-profit organization in the US devoted to the eradication of cancer, projected a total of 35,780 myeloma cases, compared to 34,470 in 2022. Therefore, the increasing occurrence of multiple myeloma catalyzes the growth of the abecma market.
Which Companies Are Leading in the Abecma Market?
Major companies operating in the abecma market include Bristol-Myers Squibb
What Are the Major Trends Shaping the Adbry/Adtralza Market?
The Abecma market is witnessing a significant thrust towards developing cutting-edge therapies like the chimeric antigen receptor T cell (CAR T) therapy to improve patient results, target particular types of cancer with higher efficacy, and broaden the treatment choices for those with recurrent or resistant multiple myeloma. CAR T therapy, an enhanced version of immunotherapy, is predominantly employed to treat specific cancer types such as leukemia and lymphoma. The technique comprises the genetic modification of a patient's T cells (a variant of white blood cells) to efficiently recognize and eradicate cancer cells. In March 2024, Bristol Myers Squibb, a pharmaceutical company based in the US, secured the European Commission's (EC) consent for Abecma (idecabtagene vicleucel; ide-cel), a CAR T-cell therapy formulated to treat adults with relapsed and refractory multiple myeloma. This endorsement particularly targets individuals who have been through at least two previous therapies, involving an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody, and who have displayed disease progression post their last treatment.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/abecma-global-market-report
What Are the Top Revenue-Generating Geographies in the Abecma Market?
North America was the largest region in the abecma market in 2024. The regions covered in the abecma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Abecma Market?
2. What is the CAGR expected in the Abecma Market?
3. What Are the Key Innovations Transforming the Abecma Industry?
4. Which Region Is Leading the Abecma Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rising Multiple Myeloma Cases Fuel Growth In The Abecma Market: Key Factor Driving The Growth In The Abecma Market here
News-ID: 4058494 • Views: …
More Releases from The Business Research Company
2025-2034 Mainframe Modernization Market Evolution: Emerging Opportunities and M …
What Is the Projected Size of the Mainframe Modernization Market by 2025?
Recent years have witnessed substantial expansion in the market dedicated to mainframe modernization, with projections indicating a climb from a valuation of $15.72 billion in 2024 up to $18.12 billion by 2025, a trajectory translating to a compound annual growth rate (CAGR) of 15.2%. This historical upward trend is fueled by several key factors, chief among them being escalating…
Accelerated Digital Transformation Fuels Expansion in the Liquid Crystal Polymer …
How Much Will the Liquid Crystal Polymer (LCP)-Based Molded Interconnect Device Market Size Increase by 2025?
The market for liquid crystal polymer (LCP)-based molded interconnect devices has experienced swift augmentation recently, projected to escalate from a value of $0.64 billion in 2024 to $0.75 billion in 2025, reflecting a compound annual growth rate (CAGR) of 17.3%. This historical expansion is largely traceable to several key factors, including the wider acceptance of…
Consistent Growth Projected for Land-Based Command, Control, Communications, Com …
How Much Is the Land-Based Command, Control, Communications, Computers, Intelligence, Surveillance, And Reconnaissance( C4ISR ) Market Expected to Expand by 2025?
The terrestrial C4ISR sector has experienced robust expansion lately, projected to increase its valuation from $32.64 billion in 2024 to $34.87 billion the following year, reflecting a steady compound annual growth rate of 6.8%. This upward trajectory in the past phase is traceable to several key factors, including a more…
Surging Application Across End Users Powers the Expansion of the Intelligent Ele …
How Large Is the Intelligent Electrical Panel Market Expected to Be by 2025?
The electrical panel segment characterized by intelligence has experienced swift expansion recently, projected to escalate its valuation from a total of $4.47 billion in the year 2024 to $4.95 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 10.7%; this upward trajectory throughout the preceding period is linked to several factors, namely the escalating need for…
More Releases for Abecma
BCMA-targeted CAR-T Cell Therapy Market Projected to Expand at 25.0% CAGR by 203 …
Los Angeles, United State: A newly published report titled "Global BCMA-targeted CAR-T Cell Therapy Market Insights, Forecast 2025 to 2031" by QY Research throws light on the industry dynamics and current and future trends that play a key role in determining the business expansion. The BCMA-targeted CAR-T Cell Therapy report also highlights the key driving factors and restraints that are impacting the growth. For a comprehensive understanding, the professionals have…
CAR-T Cell Therapy for Multiple Myeloma Market Outlook 2024-2034: Breakthrough C …
In 2024, the global CAR-T cell therapy for multiple myeloma market is valued at USD 3.1 billion and is projected to reach USD 15.4 billion by 2034, growing at a robust CAGR of 17.5% (2025-2034). This trajectory underscores CAR-T's growing role as a central pillar in multiple myeloma treatment.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71184
Market Overview: Key Highlights
Market Size (2024): USD 3.1 Billion
Forecasted Market Size (2034): USD…
CAR-T (Chimeric Antigen Receptor T-cell) therapy Market Future Business Scope An …
CAR-T (Chimeric Antigen Receptor T-cell) therapy has transformed the landscape of cancer treatment, offering a personalized and targeted approach that reprograms a patient's T-cells to attack cancer cells. Initially developed for hematologic malignancies such as B-cell lymphoma and acute lymphoblastic leukemia (ALL), the therapy is now progressing rapidly into solid tumor applications and next-generation allogeneic platforms.
With its ability to induce long-lasting remissions, CAR-T therapy has driven rapid commercial adoption. In…
Abecma Market Forecast 2025-2034: Analysing Major Trends, Opportunities, and Gro …
What industry-specific factors are fueling the growth of the abecma market?
The surge in the incidence of multiple myeloma is predicted to boost the expansion of the abecma market in the future. Multiple myeloma, a blood cancer variant, impacts plasma cells that are a particular type of white blood cell present in the bone marrow. The growing incidence of multiple myeloma can be attributed to factors like the growing elderly population,…
Global BCMA-Targeted CAR-T Cell Therapy Market Poised for Unprecedented Growth, …
The worldwide demand for BCMA-targeted CAR-T Cell Therapy continues to surge, with market valuations estimated at $1.38 billion in 2024 and projected to reach $6.88 billion by 2031, growing at a CAGR of 25.0% from 2025 to 2031. This rapid expansion is driven by increasing demand for innovative cancer treatments, particularly for multiple myeloma, where current therapies leave significant unmet medical needs.
What is BCMA-Targeted CAR-T Cell Therapy?
BCMA-targeted Chimeric Antigen Receptor…
Comprehensive Abecma Market Insights: Forecasting Size, Growth, and Competitive …
"What Is the Expected Size and Growth Rate of the Abecma Market?
In the recent years, the abecma market has marked an $XX. The market is expected to see a rise from $XX million in 2024 to $XX million in 2025, reflecting a compound annual growth rate (CAGR) of $XX%. The historic growth can be credited to factors like the approval of abecma for dealing with relapsed/refractory multiple myeloma, advancements in…
